PLANEGG-MARTINSRIED, Germany, April 24 /PRNewswire/ -- The Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) announced today that the current Supervisory Board members Dr. Robert B. O'Connell and Dr. Brian Morgan intend to resign effectively at the end of the company's annual general shareholders' meeting taking place in Munich on 5 June 2008. At the upcoming general meeting, the Supervisory Board will propose as successors the nomination of Dr. Thomas Strüngmann and Helmut Jeggle, both representatives of Santo Holding (Germany) GmbH, the largest single shareholder of 4SC AG.

Santo Holding is an investment company that, according to the notice dated 11 January 2008, has held around 32.71% of corporate shares since the end of the acceptance period for the mandatory take over offer to 4SC shareholders at the beginning of January 2008. As the largest single shareholder of 4SC AG, Santo Holding supports the growth strategy of the company and also intends on driving it forward for the long term.

In addition to Dr. Thomas Strüngmann, Helmut Jeggle is being proposed for nomination as a second representative of Santo Holding. As a graduate of business administration and an active investment manager, he would be particularly valuable to 4SC AG as an advisor for economic issues.

Dr. Ulrich Dauer, CEO of 4SC AG, thanked the departing Supervisory Board members for their many years of service, "Both have played a decisive role in the support of the strategic alignment of 4SC AG over many years and have advised the company in its development."

Dr. Robert B. O'Connell was appointed to the Supervisory Board on 31 July 2001 and currently holds the position of deputy chairman. Dr. Brian Morgan was appointed to the Supervisory Board of 4SC AG on 28 August 2003. Both Supervisory Board members are to remain affiliated with 4SC AG in an advisory capacity in the future.

About 4SC:

4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 69, the company develops novel drug candidates for inflammatory diseases, cancer and infectious diseases using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC AG utilises its technology platform, which is protected by patent, to create a sustainable project pipeline of active agents to be developed up to the early clinical phases ("proof of concept") and subsequently licensed to the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently six projects in the pipeline and a so-called ideas' pool with further development candidates. The first project for the treatment of rheumatoid arthritis has already successfully completed clinical phase IIa. Four other product candidates are in pre-clinical development and another project is in the research stage. In addition, the company is implementing its technology platform in partnerships with pharmaceutical and biotechnology companies, and is already generating initial revenues.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please contact us! Bettina von Klitzing Manager Investor Relations und Public Relations 4SC AG Tel.: +49(0)89-70-07-63-0

For more information please contact us! Bettina von Klitzing, Manager Investor Relations und Public Relations, 4SC AG, Tel.: +49(0)89-70-07-63-0,